MHRA Lowers Casgevy’s Age Floor to Five; FDA’s Is Two

CasgevyWhat to know

30-second read

For Hematology · Pediatrics

Who

Children aged 5–11 with severe sickle-cell disease or transfusion-dependent beta-thalassemia, with no matched sibling stem-cell donor.

What’s new

MHRA lowered Casgevy’s (exagamglogene autotemcel) UK age floor from 12 to 5, on direct trial data in that age band.

Evidence

CLIMB-141/-151: 11 SCD and 15 TDT children aged 5–11 dosed; evaluable SCD patients free of vaso-occlusive crises, evaluable TDT patients transfusion-independent.

Key consideration

One TDT child died of busulfan-related veno-occlusive liver disease; every treated child had a grade 3/4 adverse event. Fertility counselling is needed before conditioning.

Where it differs

FDA’s own floor is age 2, reached by extrapolating the 5–11 data rather than from trial evidence in younger children — MHRA did not extrapolate.

Access

NHS funding for the newly eligible 5–11 band is unconfirmed; the existing commercial deal was negotiated for ages 12 and over.

Practice impactRefer early where no donor match exists

A genuine option where no matched donor exists, but busulfan conditioning carries real pediatric risk and NHS funding for this band is unsettled — discuss fertility preservation before conditioning, and confirm commissioning before promising access.

Read the full physician analysis

Full analysis · 9 min readMHRA licence variation, 29 Oct 2026 · CLIMB-141/-151 (EHA 2026, NEJM) · FDA CNPV decision, 1 Jul 2026

The UK’s Medicines and Healthcare products Regulatory Agency approved a licence variation on 29 October 2026 lowering the minimum age for Casgevy (exagamglogene autotemcel; Vertex Pharmaceuticals and CRISPR Therapeutics) from 12 to five years, for severe sickle-cell disease and transfusion-dependent beta-thalassemia. It is not the first time a regulator has moved this age floor — the FDA went lower, to age two, four months earlier — but the two decisions were reached by different routes, and the gap between them is the clinically useful part of this story.

What BCL11A editing is actually doing

Casgevy is an ex vivo CRISPR-Cas9 therapy: a patient’s own CD34+ hematopoietic stem cells are collected, edited at the erythroid-specific enhancer of BCL11A — the gene that normally silences fetal hemoglobin production after birth — then reinfused after myeloablative busulfan conditioning clears the bone marrow to make room for the edited cells to engraft. Disabling that enhancer de-represses fetal hemoglobin, which does not sickle and does not require the defective beta-globin that drives both sickle-cell disease and beta-thalassemia. In the pediatric data presented at the European Hematology Association congress in June 2026, more than 98% of circulating red blood cells in treated children expressed fetal hemoglobin — the mechanism works the same way in a five-year-old as it does in an adult.

The evidence a five-year-old's family will actually see

The pediatric cohorts behind this licence variation are small and the follow-up is still accumulating. In CLIMB-151 (sickle-cell disease), 11 children aged 5 to 11 have been dosed, and the evaluable patients have been free of vaso-occlusive crises since treatment. In CLIMB-141 (transfusion-dependent beta-thalassemia), 15 children in the same age band have been dosed, and 8 with at least 16 months of follow-up had all reached at least 12 months of transfusion independence. Those are the same categorical endpoints — freedom from crises, freedom from transfusion — that supported Casgevy’s original adult and adolescent approval, and the early signal in this age band points the same direction. But these are interim numbers from a still-enrolling cohort, not a mature dataset, and the single most important safety fact belongs in this paragraph, not buried in a label: one child in the transfusion-dependent cohort died of veno-occlusive liver disease attributed to busulfan conditioning, not to the gene edit itself, and every treated child in the pediatric cohorts has had at least one grade 3 or 4 adverse event.

Why the FDA's lower floor isn't the stronger evidence

On 1 July 2026, the FDA expanded Casgevy’s U.S. label to children aged two and older, using the Commissioner’s National Priority Voucher pathway — its eighth approval under that program, cleared 53 days after filing. That sounds like a more permissive decision than MHRA’s, and in one sense it is: a UK hematologist cannot yet offer Casgevy to a 3-year-old, while a U.S. colleague can. But the FDA’s floor of two was reached by extrapolating from the same 5-to-11 trial data discussed above, not from direct efficacy evidence in two-to-four-year-olds. MHRA’s floor of five is where Vertex’s trial-evaluable pediatric data actually sits. For a hematologist discussing eligibility with a family, the honest framing is that the UK requires its own evidence to exist before extending access, while the U.S. has accepted a scientific inference that disease biology and treatment mechanism do not meaningfully differ between a 4-year-old and a 6-year-old. Neither position is unreasonable; they are different risk tolerances applied to the same underlying data, and a physician explaining this to a UK family of a 3-year-old needs to be direct about why the therapy is not available to them yet, even though it might be across the Atlantic.

A fertility conversation neither regulator settles

Busulfan conditioning is gonadotoxic, and the risk is not theoretical: in one published cohort, 7 of 10 girls who received busulfan-based conditioning as children went on to develop severe ovarian failure requiring estrogen replacement. For a prepubertal child, sperm or oocyte banking is not possible. For girls, ovarian tissue cryopreservation is an established option — reported cohorts include children as young as two to eight years old — and should be raised with families before conditioning begins. For prepubertal boys, there is currently no comparable option; testicular tissue cryopreservation remains experimental and is not a validated fertility-preservation strategy. This has nothing to do with where MHRA or FDA drew their age lines, and everything to do with what a hematologist needs to discuss with the parents of a newly eligible 5-year-old before the first appointment with a transplant unit.

Where this leaves existing options for a 5-to-11-year-old

Casgevy does not replace the existing ladder of options for severe sickle-cell disease and transfusion-dependent thalassemia in this age band — it adds a rung for children without a matched donor. Allogeneic hematopoietic stem-cell transplant from a matched sibling remains first-line when that donor exists, with a long track record children’s families and transplant teams already understand. Hydroxyurea remains the mainstay disease-modifying therapy for sickle-cell disease, reducing vaso-occlusive crises and hospitalization without the conditioning risk. Chronic transfusion with iron chelation remains standard for transfusion-dependent thalassemia. One comparator has left the field entirely: voxelotor (Oxbryta) was voluntarily withdrawn worldwide by Pfizer in September 2024 after postmarketing trials showed a mortality and vaso-occlusive-crisis safety signal, and the EU’s CHMP recommended its authorization remain suspended as recently as December 2025 — it is not an alternative to raise with a family today. Crizanlizumab (Adakveo) is labeled in the U.S. only from age 16 and so does not apply to this newly eligible band regardless.

What changes in a UK hematology clinic

• Donor-match screening becomes the gate. Casgevy is the option for a child with no matched sibling donor, not a first-line replacement for transplant where a match exists.
• Fertility counselling moves earlier. Raise ovarian tissue cryopreservation with the families of girls before conditioning; be direct with families of boys that no comparable option yet exists.
• Centre capacity matters. Treating a 5-year-old requires a unit equipped for pediatric myeloablative conditioning and the isolation period that follows, not just one credentialed to treat the existing 12-and-over population.
• Do not promise funding. NHS commissioning for the newly eligible 5-to-11 band is unconfirmed as of this licence variation; confirm commissioning status before setting expectations with a family.
• A 2-to-4-year-old is not yet eligible in the UK, unlike in the U.S. — be prepared to explain why, using the evidence-versus-extrapolation framing above.

The honest summary is that this licence variation gives real, evidence-backed access to five-to-eleven-year-olds who have exhausted or never had a donor option, while leaving two real questions open: whether the NHS will pay for it in this age band, and how a family should weigh a busulfan-related death in the pediatric safety data against disease severity that, left untreated, carries its own serious risks. Every story on this desk is filed by specialty on the For Physicians front.

Casgevy's age floor, regulator by regulator

1. 2023

   Original UK and US approvals

   Casgevy authorized for severe sickle-cell disease and transfusion-dependent beta-thalassemia, age 12 and over.

2. Jun 2026

   Pediatric data presented

   CLIMB-141/CLIMB-151 results in children aged 5-11 presented at the European Hematology Association congress.

3. 1 Jul 2026

   FDA extends to age 2

   U.S. label widened via the Commissioner's National Priority Voucher pathway, extrapolating from the 5-11 trial data.

4. 29 Oct 2026

   MHRA extends to age 5

   UK licence variation lowers the floor to match the trial-evaluable pediatric age band directly.

5. Ahead

   NHS commissioning decision

   Whether funding for the 5-11 band follows automatically or requires a new NICE appraisal remains unresolved.

Frequently asked questions

Can a 2-to-4-year-old with severe sickle-cell disease get Casgevy in the UK now?

No. MHRA's new floor is five, matching the age band where Vertex has direct, evaluable pediatric trial data. The FDA's lower floor of two was reached by extrapolating from the same 5-to-11 dataset, not from trial evidence in two-to-four-year-olds -- MHRA chose not to extrapolate below its evidence base.

Does NHS funding already cover a newly eligible five-year-old?

Not confirmed. NHS England's existing commissioning arrangement for Casgevy, including its confidential discount off the roughly £1.65 million list price, was negotiated for patients aged 12 and over. Whether it extends automatically to the 5-to-11 band or requires a fresh NICE appraisal and commercial negotiation is unresolved as of this licence variation.

What should I tell a family about fertility before busulfan conditioning in a five-year-old?

Busulfan-based conditioning carries a real risk of ovarian failure in girls, and ovarian tissue cryopreservation is an established option even at this age -- it does not require puberty. There is no comparable fertility-preservation option yet for prepubertal boys; testicular tissue freezing remains experimental. Raise this before conditioning begins, not after.